USPTO serial 97750174
W WUXI APPTEC
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 7, 2026
- Examiner
- RINGLE, JAMES W
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with W WUXI APPTEC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Wuxi, Jiangsu Province, CN
Wuxi, Jiangsu Province, CN
Wuxi, Jiangsu Province, CN
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jonathan M. Rixen
Jonathan M. Rixen Dennemeyer & Associates, LLC230 W. Monroe St.Suite 2100Chicago, IL 60606Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Acids for industrial use, namely, fatty acids, boric acid, citric acid, gallic acid, glutamic acid, hydrochloric acid, formic acid, phosphoric acid, carbonic acid, chromic acid, lactic acid, sulfuric acid, adipic acid, alpha-ketoglutaric acid, anthranilic acid, benzoic acid; caustic alkali; Chemical additives to fungicides; Biochemical catalysts; Chemical preparations for scientific purposes, other than for medical or veterinary use; Chemical preparations for analyses in laboratories, other than for medical or veterinary purposes; Diagnostic preparations, other than for medical or veterinary purposes; Reagent paper, other than for medical or veterinary purposes; Biological preparations for use in industry and science; Synthetic resins, unprocessed; Preparations of microorganisms, other than for medical and veterinary use; Adjuvants, other than for medical or veterinary purposes; Biochemical agents for scientific use | ACTIVE | Oct 27, 2025 |
| 005 | Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cancer, autoimmune disease, coagulation disorder, infectious disease; Medicines for human purposes, namely, medicines for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Raw material medicine, namely, medicines for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases; Pharmaceutical preparations, for the treatment of cancers, inflammatory diseases, autoimmune diseases, infectious diseases, and coagulation disorders; pharmaceutical preparations, namely antivirals; Chemico-pharmaceutical preparations; Biological preparations for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioural and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; Chemical preparations for the diagnosis of pregnancy; Chemical preparations for pharmaceutical or medical purposes, namely, for the treatment of cancers, inflammatory diseases, autoimmune diseases, infectious diseases, and coagulation disorders healthcare and clinical applications; Chemical preparations for medical purposes, namely chemical reagents for medical purposes; Chemical preparations for medical purposes namely, for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioural and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; Diagnostic preparations for medical purposes; Nutritional supplements; Drugs for medical purposes, namely, pharmaceuticals for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioural and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; Reagent paper for medical purposes; Medical diagnostic reagent; Disinfectants for hygiene purposes; Cultures of microorganisms for medical use; Biochemical medicines for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioural and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; Adjuvants for medical purposes; Vaccines; Veterinary preparations, namely, pain relief medication; Veterinary preparations for treatment of intestinal bacteria | ACTIVE | Oct 27, 2025 |
| 009 | Recorded computer operating programs; Recorded computer programs for use in creating searchable databases of information and data for use in the field of pharmaceutical research; Recorded computer programs for use in database management for use in the field of information technology; Recorded computer programs for organizing and viewing digital images for use in the field of cloud computing; Data processing apparatus; Magnetic encoded card readers; Intercommunication apparatus namely, virtual machine server login device; Intercommunication apparatus for voice and data transmission; Intercommunication apparatus for remote access to data; Intercommunication apparatus, namely, apparatus for transmission of communication; Laboratory trays; Test tubes; Petri dishes; Downloadable computer software platforms for application development and database management; Recorded computer software platforms for application development and database management; Laboratory robot; Laboratory equipment, namely, spectroscopes, crucibles, funnels, pipette racks and microscope slides for detecting gene sequences; Glassware for laboratory scientific test purposes; Laboratory instruments for testing pathogens and toxins in biological samples, for researching purposes; Electronic apparatus for testing the sterility of medical equipment; Electronic apparatus for testing the sterility of pharmaceuticals and injectable solutions; Laboratory apparatus and instruments, namely, pre-packed columns for use in chemical synthesis; Laboratory chemical reactors; Reactors, coils, retorts and crackers for use in high temperature chemical reactions; Instrument and measuring apparatus, namely, scales and acidity analyzers for physico-chemical experiment and composition analysis; Surveying apparatus; Surveying instruments | ACTIVE | Oct 27, 2025 |
| 010 | Medical apparatus and instruments for use in general surgery; Hematology analyzers for medical diagnostic uses; Body composition analyzers for medical purposes; medical diagnostic apparatus for testing blood sugar levels; Immunochemical testing apparatus for medical use; Medical diagnostic apparatus for detecting cancer; Ultrasound diagnostic apparatus; Medical diagnostic apparatus for testing blood sugar levels, cancer cells and DNA; Milling apparatus for dental purposes; Dental apparatus, namely, intra-oral light systems; Dental apparatus, namely, apex locator; Manually-operated resistance bands for physical therapy purposes; Electronic stimulation apparatus for nerves, skin and muscles for physical therapy purposes; Foam rollers for use in physical therapy; Belts for medical purposes; Contraceptives, non-chemical; Orthopaedic knee bandages; Orthopaedic belts; Orthopedic walkers; Orthopedic braces; Suture materials; Genetic testing apparatus for medical purposes; Apparatus for DNA and RNA exams for medical purposes | ACTIVE | Oct 27, 2025 |
| 040 | Metal treating; Processing and handling of chemical reagents, in the pharmaceutical and medical industry; mold prevention treatment of cloth; permanent press treatment of cloth; crease-resistant treatment of cloth; Paper treating; Processing of oil; applying finishes to fabric; applying finishes to textiles; applying finish to stainless steel sheets and coils; Recycling of waste and trash; Air purification; processing and treatment of medicine by means of cryogenic processing, freezing processing, drying processing, spray drying processing, fluid chemistry processing, green chemistry processing; Cryopreservation services; Providing information relating to material treatment | ACTIVE | Oct 27, 2025 |
| 042 | Computer programming; Material testing; Technical research in the field of pharmaceutical studies; Research and development of new products for others; Technology consultancy in the field of pharmaceutical preparations and medicines for medical purposes; Chemical analysis; chemistry services for industrial purposes namely, chemistry consultation and research, chemist services, pharmaceutical chemistry research; Chemical research; Biological research; Medical and scientific research, namely, conducting clinical trials for others; Quality checking and testing, namely, quality control of medicines; Quality control for others; Scientific laboratory services; Genome structure and function analysis; Research and development services in the field of gene expression systems; Biomedical research services; Stem cell research services; Drug research and development services; Culturing of cells for scientific research purposes; Design and development of computer hardware and software; Development and creation of computer programs for data processing; Computer programming in the field of medical treatment; Product quality testing; assessment of quality of products; Scientific research; Surveying; Bacteriological research; Design, development and maintenance of a computer programs; Computer software design; Computer technology consultancy; Information technology consulting relating to installation, maintenance and repair of computer software; Artificial intelligence technology consulting; Research in the field of artificial intelligence technology; Research and development of new products; Pharmaceutical research services; Development of pharmaceutical preparations and medicines; Vaccine research and development services; Cancer medicine research; Biotechnology research; Pharmaceutical product evaluation; Medical and scientific research in the field of cancer treatment and diagnosis; Development and Test of Chemical production methods; Conducting early evaluations in the field of new pharmaceuticals; Biochemical research and analysis; Chemical analysis evaluation service; Research of the mode of action of chemical combinations on animals | ACTIVE | Oct 27, 2025 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by WuXi AppTec Co., Ltd.
- Other trademarks owned by WuXi AppTec Co., Ltd.
- Other trademarks owned by WuXi AppTec Co., Ltd.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named W WUXI APPTEC
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 7, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 7, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 15, 2026 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jun 15, 2026 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jun 12, 2026 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jun 12, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Mar 5, 2026 | IUAF | USE AMENDMENT FILED | — |
| Mar 5, 2026 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Sep 15, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 2, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Sep 2, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| Sep 2, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 9, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 14, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 13, 2025 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 13, 2025 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 13, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 22, 2025 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Jan 22, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 22, 2025 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Jan 22, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 22, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 26, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 26, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 26, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 26, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 12, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 16, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 16, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 27, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 8, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 6, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 6, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 6, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 6, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 28, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 28, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 28, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 27, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 27, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Nov 27, 2023 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Nov 27, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 27, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 12, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 12, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 12, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 5, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 2, 2023 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Feb 1, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 18, 2023 | TAEA | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | — |
| Jan 18, 2023 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jan 14, 2023 | NWAP | NEW APPLICATION ENTERED | — |